Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance
about
Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosisRIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosisXIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative diseaseSmall-molecule SMAC mimetics as new cancer therapeuticsGetting TRAIL back on track for cancer therapyGlycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosisInduction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance.Molecular targets for selective killing of TRAIL-resistant leukemic cells.Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cellsTherapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatmentThe transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xLA promising "TRAIL" of tanshinones for cancer therapy.Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeuticsMicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid MalignanciesHow to target apoptosis signaling pathways for the treatment of pediatric cancersPentoxifylline and the proteasome inhibitor MG132 induce apoptosis in human leukemia U937 cells through a decrease in the expression of Bcl-2 and Bcl-XL and phosphorylation of p65.Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia.Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs.The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways.MiR-424 and miR-27a increase TRAIL sensitivity of acute myeloid leukemia by targeting PLAG1Caspase-9 activation by the apoptosome is not required for fas-mediated apoptosis in type II Jurkat cells.The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells.Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers.The LEF1/CYLD axis and cIAPs regulate RIP1 deubiquitination and trigger apoptosis in selenite-treated colorectal cancer cells.Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies.The three Rs along the TRAIL: resistance, re-sensitization and reactive oxygen species (ROS).XIAP antisense therapy with AEG 35156 in acute myeloid leukemia.Inhibitor of apoptosis proteins in pediatric leukemia: molecular pathways and novel approaches to therapy.Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities.Prognostic significance of B-cell lymphoma 2 expression in acute leukemia: A systematic review and meta-analysis.X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy.Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.Nicotinamide adenine dinucleotide (NAD+) repletion attenuates bupivacaine-induced neurotoxicity.Highlights of the third International Conference on Immunotherapy in Pediatric Oncology.Regulation of cell death in cancer-possible implications for immunotherapy.Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas.PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.RIP1 protein-dependent assembly of a cytosolic cell death complex is required for inhibitor of apoptosis (IAP) inhibitor-mediated sensitization to lexatumumab-induced apoptosis.
P2860
Q24294685-F24F0CDC-3705-4490-9C4B-F41CC72E8F1EQ24299986-1648E3D5-7E10-4668-879A-64194646A31CQ24610800-9346CE2C-00C4-4E21-8B13-9E36881A83E1Q26864204-4D50A09D-0CD4-4206-937E-55F20688529AQ27027460-292B0D69-F9FD-4B51-A90F-0E3AC171A795Q28729017-B4BC96AB-0A0F-401B-AB80-AB9EF09BFA9CQ33755338-12D80CE4-B021-4888-92F7-25A91053E27EQ33891400-4B3292D1-FB39-4647-B129-E6F85F354724Q34512395-DFA4BB25-7DA4-446D-A44B-CB398301AAEDQ34970050-988AAF01-9B4B-48E0-BFDB-79D65631A9BAQ36294675-01C6EFC3-09B4-4289-AB44-15A11955C5F0Q36332681-59930D56-FE21-4430-ACF1-FFA676195BCDQ36501732-FBF5CABA-040D-4390-A908-90997070263DQ36602853-3264C3E3-342D-4AC8-AA64-FCF99917B351Q36610528-128D4AC6-C8C8-4FD8-930A-7E04E7A876BAQ36744894-9014F968-B736-49B3-8FF5-B1D27529980EQ36751715-92E57918-1CA7-443B-8FB2-8382112A50E2Q36992161-0EAA305A-D332-42AE-8CD4-E97F5974285AQ36992184-77D7182D-3BDD-4848-8BD6-358F09CC53AFQ37061991-2DCB2F23-BFAC-44D5-B77F-7B2916D40B6EQ37295313-F0045252-5954-45E3-BCB8-9CB2BC10C70EQ37446194-4F40C4B0-10A1-4016-B3BA-BD46EF9FACA8Q37564440-C1BB406E-6A6F-4182-AFE1-BE3490CA4529Q37580273-1EED8DA1-D4C2-4D7F-BEDD-AE34ED4A32A3Q37620626-8D360CE7-0BCB-42CE-A9AD-523D01D2D42CQ37974461-B5C579B1-7765-43DD-8B2E-0DF810B3AED4Q38007570-C64A6839-5E6C-4787-8076-DC8D377B038CQ38099047-56F2DD3E-F2B8-46EC-A44F-2D9437483BA6Q38183402-4FC4B368-5B96-4820-B862-6F895BE921E1Q38184343-FE9A6A5B-94A3-4283-B8AE-DD6D2B136550Q38207607-C733AE31-592C-4C77-913C-AF9F426B6101Q38239689-353C748A-B26F-424D-BF39-C9912EF35867Q39096643-5E2EE0F5-8ED4-4CEF-8EA8-3E659564F64DQ39131924-62390D83-004D-4187-A18B-DBDD04C5023EQ39403785-71415CCC-846E-44CB-921E-9E1F1623C895Q39461469-E43D5C33-0B80-4C04-97C2-5370E3850641Q39467184-E05485E6-A705-47E2-BF96-2EB228403214Q39653523-85EC655D-3D0D-4843-9BFD-6BF326F312FDQ39682910-CA13AC47-EFE5-4361-BCC7-21437BA88C7AQ41311490-06F48EC8-CB52-4845-BA69-658F0354CD8E
P2860
Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance
description
im November 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 25 November 2008
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2008
@uk
name
Small molecule XIAP inhibitors ...... come Bcl-2-mediated resistance
@en
Small molecule XIAP inhibitors ...... come Bcl-2-mediated resistance
@nl
type
label
Small molecule XIAP inhibitors ...... come Bcl-2-mediated resistance
@en
Small molecule XIAP inhibitors ...... come Bcl-2-mediated resistance
@nl
prefLabel
Small molecule XIAP inhibitors ...... come Bcl-2-mediated resistance
@en
Small molecule XIAP inhibitors ...... come Bcl-2-mediated resistance
@nl
P2093
P50
P1433
P1476
Small molecule XIAP inhibitors ...... come Bcl-2-mediated resistance
@en
P2093
Katja Schneider
Meike Vogler
Melanie Fakler
Sandra Loeder
P304
P356
10.1182/BLOOD-2007-09-114314
P407
P577
2008-11-25T00:00:00Z